Home

Kerry Wentworth

CIK 1369453 · CHIEF REGULATORY OFFICER · last filed 2026-06-24

Kerry Wentworth is a CHIEF REGULATORY OFFICER who has filed 75 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for NUVB, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $330.0K across reported positions. 47 SEC filings were submitted jointly with AGENUS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$330.0K

Companies

4

Total Filings

75

Lifetime Open-Market Net

-$1.58M

Filer Profile

Reported Address
NUVATION BIO INC.
1500 BROADWAY, SUITE 1401
NEW YORK, NY 10036
Related Filers
AGENUS INC — 47 joint filings, latest 2014-02-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NUVB CHIEF REGULATORY OFFICER 53,000 $5.76 $305.3K -$1.47M 4 2026-06-24
Nuvation Bio Inc. (NUVB.WS) Delisted CHIEF REGULATORY OFFICER 50,000 $0.01 $255 $89.7K 6 2025-06-18
FLXN Chief Regulatory Officer 0 $24.21 $0 -$109.1K 17 2021-11-19
AGEN VP, Clinical, Reg & Qual 2,870 $8.60 $24.7K -$90.9K 45 2014-02-28

Recent Filings

75 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 NUVB Mixed — -$194.6K EDGAR
2026-06-23 NUVB Notice (144) −63,000 -$362.9K EDGAR
2026-04-21 NUVB Mixed — -$76.6K EDGAR
2026-04-17 NUVB Notice (144) −36,750 -$176.8K EDGAR
2026-04-08 NUVB Mixed — -$522.6K EDGAR
2026-04-06 NUVB Notice (144) −200,000 -$882.0K EDGAR
2026-03-03 NUVB Grant (A) — $0 EDGAR
2025-06-18 Nuvation Bio Inc. (NUVB.WS) Delisted Buy (P) +50,000 $89.7K EDGAR
2025-03-04 Nuvation Bio Inc. (NUVB.WS) Delisted Grant (A) — $0 EDGAR
2024-03-04 Nuvation Bio Inc. (NUVB.WS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 75
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.